Catalent Stock Forecast for 2023 - 2025 - 2030
Updated on 02/05/2023
Catalent Stock Forecast and Price Target
The average price target of $73.00 for Catalent's stock set by seven distinguished analysts in recent weeks would represent a potential upside of approximately 30.24% from the last closing price in February, 2023 if reached by the end of the year. This potential increase is based on a high estimate of $100.00 and a low estimate of $58.00. Even if you are not interested in CTLT stock, it is still imperative to be aware of its competitors.
30.24% Upside
Catalent Fair Value Forecast for 2023 - 2025 - 2030
Catalent's Price has seen impressive growth In the last three years, rising from $55.89 to $118.58 – a growth of 112.15%. According to the 0 analysts polled, in the next year, Catalent's Fair Value will fall by 21.88%, reaching $92.63. By 2030, professionals believe that Catalent's Fair Value will have decreased by 20.23%, falling to $94.59.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| TMO Stock Forecast | Thermo Fisher Scientific Inc | Outperform |
10
|
$587.76 | $618.99 | 5.49% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
10
|
$111.79 | $120.97 | 11.82% |
| A207940 Stock Forecast | Samsung Biologics | Buy |
16
|
₩808.00k | ₩0.00 | 36.14% |
| IQV Stock Forecast | IQVIA Holdings | Buy |
16
|
$237.18 | $257.89 | 9.62% |
| 603259 Stock Forecast | WuXi AppTec | Buy |
18
|
¥87.57 | ¥0.00 | 56.21% |
Catalent Revenue Forecast for 2023 - 2025 - 2030
Catalent's Revenue has seen impressive growth In the last three years, rising from $2.52B to $4.83B – a growth of 91.74%. According to the 0 analysts polled, in the next year, Catalent's Revenue will fall by 19.47%, reaching $3.89B. By 2030, professionals believe that Catalent's Revenue will have decreased by 17.19%, falling to $4.00B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| LONN Stock Forecast | Lonza Group Ltd | Outperform |
16
|
CHF457.90 | CHF756.46 | 71.98% |
| 2269 Stock Forecast | WuXi Biologics (Cayman) | Buy |
14
|
HK$66.05 | HK$0.00 | 36.50% |
| DGX Stock Forecast | Quest Diagnostics | Hold |
10
|
$142.81 | $147.77 | 1.18% |
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ICLR Stock Forecast | ICON Public | Outperform |
16
|
$200.45 | $0.00 | 34.45% |
| VTRS Stock Forecast | Viatris | Outperform |
8
|
$12.18 | $13.70 | 10.84% |
| ERF Stock Forecast | Eurofins Scientific | Hold |
18
|
66.16€ | 0.00€ | 58.71% |
Catalent Free Cash Flow Forecast for 2023 - 2025 - 2030
Catalent's Free Cash Flow has decreased In the last three years, from $30.00M to $-221.00M – a 836.67% drop. Analysts predict that Catalent's Free Cash Flow will increase in the upcoming year, reaching $-324.24M. This would represent an increase of 46.71%. Over the next eight years, experts predict that Catalent's Free Cash Flow will grow at a rate of 12.05%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| 300759 Stock Forecast | Pharmaron Beijing | Outperform |
16
|
¥74.72 | ¥0.00 | 107.23% |
| CRL Stock Forecast | Charles River Laboratories Int... | Outperform |
16
|
$250.35 | $268.54 | 3.85% |
| 500124 Stock Forecast | Dr. Reddy's Laboratories | Outperform |
18
|
Rp4.27k | Rp5.47k | 15.97% |
Catalent Net Income Forecast for 2023 - 2025 - 2030
In the last three years, Catalent's Net Income has grown, moving from $137.00M to $519.00M – an increase of 278.83%. According to 0 prominent analysts, Catalent's Net Income will fall by 29.17% in the next year, reaching $367.61M. By 2030, professionals believe that Catalent's Net Income will decrease by 16.99%, reaching $430.81M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| 002821 Stock Forecast | Asymchem Laboratories (Tianjin... | Buy |
16
|
¥166.30 | ¥0.00 | 155.89% |
| 603456 Stock Forecast | Zhejiang Jiuzhou Pharmaceutica... | Buy |
18
|
¥43.51 | ¥0.00 | 58.19% |
| PRGO Stock Forecast | Perrigo | Buy |
16
|
$37.20 | $47.75 | 27.69% |
Catalent EBITDA Forecast for 2023 - 2025 - 2030
Catalent's EBITDA has seen growth In the last three years, going from $522.00M to $1.13B – a gain of 115.65% According to 0 major analysts, Catalent's EBITDA will fall by 22.33% in the next year, reaching $874.35M. Professionals believe that By 2030, Catalent's EBITDA will fall to $914.68M– a 18.74% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| 300363 Stock Forecast | Porton Pharma Solutions | Buy |
18
|
¥51.12 | ¥0.00 | 131.81% |
| EVT Stock Forecast | Evotec | Outperform |
14
|
18.92€ | 37.33€ | 74.42% |
| SYNH Stock Forecast | Syneos Health | Outperform |
16
|
$37.93 | $90.75 | -10.36% |
Catalent EBIT Forecast for 2023 - 2025 - 2030
In the last three years, EBIT for Catalent has grown by 157.68%, going from $293.00M to $755.00M. In the next year, 0 analysts estimate that Catalent's EBIT will decrease by 26.23%, reaching $556.94M. According to professional forecasts, in 2030, Catalent's EBIT will decrease by 20.09%, reaching $603.29M.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| EBS Stock Forecast | Emergent BioSolutions | Outperform |
16
|
$13.97 | $44.50 | 168.43% |
| CDMO Stock Forecast | Avid Bioservices | Outperform |
12
|
$16.19 | $28.25 | 72.95% |
| LH Stock Forecast | Laboratory Corp of America Hol... | Outperform |
11
|
$251.71 | $278.38 | 9.25% |
Catalent EPS Price Prediction Forecast for 2023 - 2025 - 2030
Catalent's EPS has seen impressive growth In the last three years, rising from $1.81 to $3.84 – a growth of 112.15%. According to the 0 analysts polled, in the next year, Catalent's EPS will fall by 21.88%, reaching $3.00. By 2030, professionals believe that Catalent's EPS will have decreased by 20.23%, falling to $3.06.